Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Too much vitamin B6 and B12 tied to hip fractures in older women

Older women who take supplements with high doses of vitamins B6 and B12 may be more likely than their counterparts who do not to experience hip fractures, a U.S. study suggests.

Read More »

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Read More »

FDA Approves Evenity For Treating Osteoporosis In Postmenopausal Women At High Risk For Fracture

Amgen and UCB announced that the U.S. FDA approved Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Read More »

Taking vitamin D supplements may not improve bone health

Vitamin D supplementation may not improve bone density or prevent fractures and falls in adults, a large new analysis suggests.

Read More »

Amgen, UCB Resubmit Biologics License Application For Evenity To U.S. FDA

Amgen and UCB announced the resubmission of the Biologics License Application to the U.S. FDA for Evenity (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Read More »

U.S. Supreme Court to hear Merck appeal over Fosamax suits

The U.S. Supreme Court agreed to hear Merck & Co.’s appeal of a lower court’s ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

Read More »

Supplements may not lower fracture risk

Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who do not use these supplements per a research review.

Read More »

Safety Issues Force the FDA to Turn Down Amgen, UCB’s Osteoporosis Drug

The U.S. Food and Drug Administration rejected Amgen’s and UCB’s Biologics License Application for Evenity (romosozumab) for postmenopausal women with osteoporosis.

Read More »

Merck scraps development of osteoporosis drug

Merck & Co. Inc. said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.

Read More »

Even low-levels of common metal linked to weaker bones

(Reuters Health) – Low levels of exposure to the metal cadmium may increase the risk of weaker bones and fractures in elderly men, a Swedish study suggests. Cadmium is a naturally occurring metal used in batteries and found in cigarette smoke and exhaust from fossil fuels or waste incineration. As a result of crops grown […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom